Welcome to this week's Chutes and Ladders, our roundup of hirings and firings throughout the industry. Please send the good word--or the bad--from your shop to Michael Gibney (email | Twitter) or Emily Mullin (email | Twitter) and we will feature it here at the end of each week.
Teva chairman Frost will leave by the end of the year
Teva chairman Dr. Phillip Frost announced he would step down from the position "approximately by the end of this year," he wrote in a letter to shareholders. Frost happens to be Teva's largest individual shareholder with a stake worth $725 million and was due to retire in about a year, according to Reuters. "With the progress we have made, and continue to make, at Teva, I have advised the board that I believe it will be appropriate for me to step down as chairman," Frost said. Story
|
||||||||||||||||
Biotech
> InVivo Therapeutics ($NVIV) has appointed Steven McAllister as chief financial officer. Release
> Regulus Therapeutics ($RGLS) appointed Dr. Paul Grint as its chief medical officer. Release
> Celerion named Dr. Robert Lester as the company's chief cardiologist and global medical director of cardiac safety services. Release
> Florida-based InformedDNA named Duffy Oelberg its senior vice president for business development. Release
> True North Therapeutics announced that Dr. James Gilbert will take over as chief medical officer. Release
> Retrogenix has appointed Matthew Britz as its North American business development director. Release
> Stephen Tulipano has joined Aldeyra Therapeutics ($ALDX) as the company's chief financial officer. Release
> Stephen Ritter has joined Emotient as senior vice president of product development. Release
> Neurotrope ($NTRP) has appointed Charles Ramat and Paul Frieman as co-chairmen of its board of directors. Release
> Sangamo Biosciences ($SGMO) has appointed H. Stewart Parker to its board of directors. Release
> Thrasos Therapeutics has appointed Donald Notman as chief financial officer and senior vice president. Release
> Novavax ($NVAX) has appointed John Marsh Jr. as director emeritus of its board. Release
> Algae Biomass Organization has appointed Matthew Carr as executive director. Release
> Regado Biosciences ($RGDO) has named Drew Fromkin to its board of directors. Release
> Sorbent Therapeutics has appointed Jay Shepard and William Waddill to the company's board of directors. Release
> Dan Baker has joined Remedy Informatics as the company's senior vice president of sales. Release
> Oxford BioTherapeutics has appointed Dr. Keith Wilson as chief scientific officer. Release
> CannaVest ($CANV) has hired Stuart Tomc to spearhead the company's consumer health education and product development. Release
> Chris Collins has joined Piper Jaffray as principal in its biotechnology investment banking group. Release
Pharma
> Valeant's ($VRX) executive vice president, Ryan Weldon, will be leaving the company. Release
> South San Francisco's Global Blood Therapeutics has named Dr. Ted Love as its new CEO. Release
> Cardax has scooped up George Bickerstaff, former CFO of Novartis Pharma AG ($NVS), Tamar Howson, former senior business development executive at Bristol-Myers Squibb ($BMY) and SmithKline Beecham, and Terence Kelly, former senior Boehringer Ingelheim anti-inflammatory R&D executive and current CEO of CoMentis, as independent members of its board of directors. Release
> Sweden's Cantargia has named Dr. Goran Forsberg as CEO. Release
> Aerie Pharmaceuticals ($AERI) announced that Craig Skenes is its new vice president of business development. Release
> Horizon Pharma ($HZNP) has named Paul Hoelscher as its chief financial officer and executive vice president, finance. Hoelscher will take the place of Robert De Vaere, the company's current chief financial officer. Release
> Erytech Pharma appointed Dr. Martine George and Hilde Windels as independent members of its board of directors. Release
> Brandon Kocher has joined Viscadia as an associate consultant. Release